Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CBX7 | O95931 | 4/20 | 0.52 |
| ▸ | CDYL | Q9Y232 | 4/20 | 0.52 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 4/20 | 0.52 |
| ▸ | CDYL2 | Q8N8U2 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25307601 | 0.86 | L3MBTL1 (0.58) | L3MBTL1CBX7CDYLCDY1; CDY1BCDYL2 | |
| SCHEMBL20472305 | 0.81 | CBX7 (0.54) | L3MBTL1CBX7CDYLCDY1; CDY1BCDYL2 | |
| SCHEMBL30660243 | 0.81 | CBX7 (0.54) | L3MBTL1CBX7CDYLCDY1; CDY1BCDYL2 | |
| SCHEMBL16932296 | 0.79 | CBX7 (0.60) | L3MBTL1CBX7CDYLCDY1; CDY1BCDYL2 | |
| SCHEMBL30538038 | 0.79 | CBX7 (0.60) | L3MBTL1CBX7CDYLCDY1; CDY1BCDYL2 | |
| SCHEMBL22315069 | 0.79 | L3MBTL1 (0.53) | L3MBTL1 | |
| SCHEMBL5422054 | 0.78 | CBX7 (0.54) | L3MBTL1CBX7CDYLCDY1; CDY1BCDYL2 | |
| SCHEMBL30660242 | 0.78 | CBX7 (0.62) | CBX7CDYLCDY1; CDY1BCDYL2SIGMAR1 | |
| SCHEMBL5416540 | 0.78 | CBX7 (0.62) | CBX7CDYLCDY1; CDY1BCDYL2SIGMAR1 | |
| SCHEMBL22315055 | 0.78 | L3MBTL1 (0.52) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219938-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | L3MBTL1 1392/4885CBX7 1133/4885CDYL 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.